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Background: C-reactive protein (CRP) measurement has proven valuable for detecting 
exacerbations, but its usefulness in predicting etiology remains controversial. Likewise, its 
potential value as a marker of severity, which is well established in patients with pneumonia, 
remains unproven in chronic obstructive pulmonary disease (COPD) exacerbations.
Methods: A cohort study of 118 patients with severe COPD and acute infectious exacerbations 
were included and followed up over 1 year. Episodes of exacerbations meeting Anthonisen’s 
criteria type I–II were evaluated, analyzing the etiology and inflammatory response as measured 
by CRP in blood.
Results: A total of 380 episodes were recorded. Full microbiological analysis was available in 
265 samples. Haemophilus influenzae was the most commonly isolated bacteria and rhinovirus 
the most common virus. Median CRP levels from the 265 episodes were higher in the cases with 
positive cultures for bacteria (58.30 mg/L, interquartile range [IQR] 21.0–28.2) than in episodes 
only positive for viruses (37.3 mg/L, IQR 18.6–79.1) and cases negative for any microorganism 
(36.4 mg/L, IQR 10.8–93.7) (P,0.014). H. influenzae and Streptococcus pneumoniae reached 
the highest CRP levels of 74.5 mg/L (IQR 23.9–167.9) and 74.1 mg/L (IQR 42.0–220.7), 
respectively. In the 380 exacerbations studied, 227 (~60%) were community-managed, while 
153 (~40%) required hospital admission. In the multivariate analysis to assess the influence 
of inflammatory response on exacerbation severity, baseline hypercapnia (odds ratio [OR]: 
2.70, 95% confidence interval [CI]: 1.46–4.9) and CRP levels .100 mg/L (OR: 4.23, 95% CI: 
2.12–8.44) were independent predictors after adjustment for baseline characteristics.
Conclusion: CRP level was higher in bacterial infections, especially when H. influenzae and S. 
pneumoniae were isolated. CRP values .100 mg/L were associated with a fourfold increased 
risk of hospital admission. Therefore, CRP blood levels may be a useful biomarker in the man-
agement of exacerbations appearing in patients with severe disease.
Keywords: COPD exacerbations, C-reactive protein, viruses, hospital admission
Introduction
In the natural history of chronic obstructive pulmonary disease (COPD), exacerbations 
have a significant impact on mortality,1 especially in those who require hospital admis-
sion. Indeed, exacerbations become more frequent and more severe as the severity 
of COPD increases.2 Although exacerbations have multiple causes, an infectious 
etiology is by far the most frequent, with figures up to 78% for hospital-admitted 
COPD patients.3 Bacterial infections account for one-half of the acute episodes, while 
respiratory viruses are identified in more than one-quarter, with rhinovirus (RV) and 
influenza being the most commonly detected viral pathogens. Microbiological studies 
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have identified change in sputum color and purulence as 
good surrogate markers for bacterial infection,4,5 while the 
detection of viruses in exacerbations is only marginally 
associated with the appearance of changes in the charac-
teristics of sputum.6,7 Both respiratory bacteria and viruses 
are able to produce major local and systemic inflammatory 
responses, and biomarkers such as C-reactive protein (CRP) 
have been extensively studied and used as an alternative 
test to diagnose bacterial infections in both COPD and 
pneumonia.8,9 Likewise, in stable COPD, CRP levels have 
been examined as a marker of bacterial colonization and/or 
subclinical infection10 but in studies of exacerbated COPD 
patients, including viral etiology, they have proven unable 
to distinguish virus-associated exacerbations from others.7 
In fact, a recent study by Clark et al demonstrated a higher 
level of CRP in exacerbations due to viruses than in those 
with positive cultures for bacteria.11
Few studies have evaluated the usefulness of CRP as a 
predictor of the severity of acute episodes. Studies that have 
suggested that high CRP levels are a marker of exacerbation 
in COPD have not demonstrated its value for the identifica-
tion of episodes severe enough to require admission.12 In 
severe COPD outpatients, studies of CRP are scarce, and 
the relationship between microorganisms and the severity 
of exacerbations is not fully understood.
The aim of the present study was to identify the causative 
microorganism (either bacterium or virus) in Anthonisen 
type I–II13 exacerbation episodes in a cohort of severe 
COPD outpatients. We evaluated the systemic inflammatory 
response as measured by CRP blood levels and assessed their 
impact on the severity of the episode, measured as the need 
for hospital admission.
Materials and methods
Outpatients from a Severe COPD Cohort regularly attend-
ing a Respiratory Diseases Day Care Unit for scheduled and 
exacerbation visits from 200514,15 were the target popula-
tion for the present study. Patients included in the cohort 
had scheduled visits and received education on self-care of 
the disease and a personal action plan, with unscheduled 
visits when exacerbation symptoms appeared, as described 
elsewhere.14 Inclusion criteria for the study were a baseline 
forced spirometry showing a forced expiratory volume 
in 1 second (FEV
1
) ,50% of the reference value and the 
report of three or more exacerbations in the previous year. 
Age ,40 years, previous diagnosis of asthma, cystic fibro-
sis, cancer, bronchiectasis diagnosed from a previous chest 
X-ray, and chronic treatment with oral corticosteroids, 
immunosuppressive drugs, or long-term systemic or inhaled 
antibiotic therapy were exclusion criteria for the study. Ethi-
cal permission for the study was obtained from the Sabadell 
Hospital Ethics Committee and written informed consent 
was given by each participant on enrollment.
Clinical variables
At baseline, smoking history, severity of the disease, Body-
mass, airflow Obstruction, Dyspnea, and Exercise index,16 
comorbidities (Charlson Comorbidity Index),17 and use of 
long-term home oxygen therapy was recorded. COPD was 
defined as a post bronchodilator ratio of FEV
1
 to forced vital 
capacity of ,0.7 according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria, in a patient with a 
smoking habit of .10 pack-years.18 A computed tomography 
scan was obtained as part of the patient’s baseline characteriza-
tion in order to identify undiagnosed bronchiectasis, grading its 
extension in accordance with previously reported criteria.14
Participants from the Severe COPD Cohort underwent 
the same scheduled clinical controls performed by the same 
team of pulmonologists at the respiratory daycare unit. They 
received regular treatment with long-acting beta-agonists, 
anticholinergics, and inhaled corticosteroids in accordance 
with current guidelines,18 and attended the unit for unsched-
uled visits when acute symptoms appeared. All visits were 
recorded, together with hospitalizations and mortality due 
to respiratory causes.
Exacerbations suffered by patients from the Severe COPD 
Cohort participating in the study were the target for the pres-
ent study. Episodes that required an unscheduled visit at the 
unit and met more than two Anthonisen’s criteria13 between 
January 2005 and March 2008 were considered for the study. 
In all episodes, acute symptoms were recorded, together with 
fever, respiratory rate (RR), and upper respiratory symptoms 
(nasal congestion, increased rhinorrhea, or sore throat). 
A chest X-ray was performed to rule out pneumonia.
Blood analyses, including blood counts, renal func-
tion, electrolytes, CRP levels, and arterial gases, were 
performed in all exacerbations, and a spontaneous sputum 
sample was obtained before the administration of antibiot-
ics. Decisions regarding treatment and admission were left 
to the discretion of attending physicians, and were taken 
in accordance with international guidelines.18,19 Exacerba-
tions were considered severe in the presence of criteria for 
hospital admission.20
Episodes in which prior antibiotic or corticosteroids 
were administered (,5 days) were excluded from the final 
analysis.21
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sputum samples
Spontaneous sputum samples were collected from each 
exacerbation and processed within 60 minutes of collection. 
Murray–Washington criteria were used for the identifica-
tion and selection of samples representative of bronchial 
secretions.22 Sputum samples graded Murray IV–V were cul-
tured for potentially pathogenic microorganisms (PPMs) in 
selective media according to standard methods, and cultures 
were considered positive when PPMs were recovered.23
Briefly, samples were vortexed for 30–60 seconds after 
homogenization with sputolysin and 10 µL of the solution 
obtained was cultured using a calibrated loop in blood agar, 
blood agar with nalidixic acid, chocolate agar, and McConkey 
agar plates. All plates were incubated in a 5% carbon 
dioxide incubator at 35°C (MacConkey agar under aerobic 
conditions) and read at 18 and 48 hours. Gram-negative 
and Gram-positive bacteria recognized as agents causing 
respiratory infections, such as Haemophilus influenzae, 
Haemophilus parainfluenzae, Streptococcus pneumoniae, 
Moraxella catarrhalis, Pseudomonas aeruginosa, Staphy-
lococcus aureus, and Enterobacteriaceae, were considered 
as PPMs.24
The number of colony forming units per milliliter of 
sputum was calculated from the number of colonies obtained 
and the dilution of the sputum. Bacteriology data are 
expressed as the total bacterial count in log base 10.
Viral DNA/RNA was extracted from 200 µL of respira-
tory clinical samples previously liquefied with Sputasol® 
(Oxoid Limited, Basingstoke, UK) in a 37°C water bath for 
20 minutes. Then, DNA/RNA was extracted using QIAmp 
MinElute Virus Spin procedure on the QIAcube® (Qiagen, 
Hilden, Germany) obtaining 50 µL of nucleic acid elute.
A multiplex retrotranscriptase-nested polymerase chain 
reaction (RT-PCR) assay was used for simultaneous detec-
tion of parainfluenza virus (1, 2, 3, 4AB), human coronavirus 
229E and OC43, enterovirus, RV, influenza virus A, B, C, 
respiratory syncytial virus (RSV), and adenovirus following 
the procedure described by Coiras et al.25
statistical analysis
Data were analyzed using GraphPad PRISM version 7.0 
(GraphPad Software Inc., San Diego, CA, USA) and 
PASW Statistics version 21 (SPSS Inc., Chicago, IL, USA). 
Results for categorical variables were expressed as absolute 
and relative frequencies, and continuous variables were 
expressed as mean values and standard deviations (SDs) or 
median and interquartile ranges (IQRs) when distribution 
was non-normal.
We used a generalized estimating equation (GEE) 
logistic model with an exchangeable within-patient cor-
relation structure and robust standard errors to account for 
individual patients with multiple exacerbations. The GEE 
logistic regression model was used to analyze factors asso-
ciated with hospital admission. In the model we included 
all patient-related covariates that were judged a priori to be 
clinically relevant and those with a P-value ,0.1. Correla-
tions between pairs of predictors were examined to ensure 
the absence of multicollinearity in the model. Odds ratio 
and their confidence intervals were estimated with 95% 
confidence. For all GEE analyses, a univariate analysis was 
carried out first.
Results
Patient characteristics
One hundred eighteen patients from the Severe COPD 
Cohort met the inclusion criteria for the study. The study 
population was predominantly male, with a mean (SD) age 
of 69 (8) years, and over half of the cases were classified as 
GOLD IV. Their baseline clinical characteristics are shown 
in Table 1. A total of 386 sputum samples were obtained 
during exacerbations meeting $2 Anthonisen criteria in the 
follow-up period, with a median exacerbation rate of 1.70 
(IQR 0.90–2.66) episodes per year. A single exacerbation 
was reported in 44 patients, whereas 24 presented two and 
Table 1 Baseline and clinical characteristics of 118 patients with 
severe COPD and acute infectious exacerbations
Subjects N=118
Follow-up (days) 1,003±306
age (years) 69.5±8.2
Current smoking 13 (11)
Pack-years 63.3±31.9
alcohol abuse .80 g/l 3 (2.5)
Influenza vaccination 105 (89)
Pneumococcus vaccination 57 (48.3)
Body mass index (kg/m²) 27.5±4.6
FeV1 post-BD (l) 0.97±0.3
FeV1 post-BD (% predicted) 34±11
gOlD stage IV 71 (60)
BODe score 5.1±1.6
Basal hypercapnia 49 (41.5)
lTOT 50 (42.4)
Charlson Comorbidity Index 4.13±1.5
Bronchiectasis 56 (47.5)
Notes: Data are presented as mean ± sD or n (%), unless otherwise stated. 
Hypercapnia defined as PaCO2 .5.9 Kpa.
Abbreviations: BODE, Body-mass index, airflow Obstruction, Dyspnea, and 
exercise index; COPD, chronic obstructive pulmonary disease; FeV1, forced 
expiratory volume in 1 second; gOlD, global Initiative for Chronic Obstructive lung 
Disease; lTOT, long-term oxygen therapy; m, mean; post-BD, post bronchodilator; 
sD, standard deviation.
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the remaining 50 presented three or more. Six episodes 
were excluded from further analysis due to corticosteroid 
treatment and/or antibiotic treatment in the last 5 days 
before the current episode. Of the remaining 380 episodes, 
227 (60%) were community-managed, with oral antibiotics 
and/or corticosteroids (96.5% and 59%, respectively), while 
153 episodes (40%) were considered severe and required 
hospital admission.
Microbiology
From a total of 380 sputum samples collected, full micro-
biological analyses were possible from 265 exacerbations 
providing samples valid for analysis according to Murray–
Washington criteria and harboring enough material to 
perform RT-PCR (Figure 1). Pathogenic bacteria were cul-
tivated from 167 (63%) of the episodes, with H. influenzae 
(n=66), S. pneumoniae (n=28), M. catarrhalis (n=28), and 
P. aeruginosa (n=28) being the most frequently recov-
ered species. In 96 samples (36%), viruses were detected; 
RV was the most common (56) followed by parainflu-
enzae (17), influenza virus (9), coronavirus (7), RV (5), 
and adenovirus (2). Viruses were identified from 45 of the 
98 samples with negative cultures for bacteria (45.9%) and 
from 51 of the 167 exacerbations with cultures showing bac-
terial infection (30.5%), which were accordingly considered 
as coinfections. In these episodes, the relationships between 
bacterial type and viruses detected did not show statistical 
significance (P=0.9).
Seasonal virus distribution demonstrated a higher preva-
lence of virus infections during fall and winter. RVs were 
present at all times of year, while parainfluenza, influenza, 
and RSV were predominately isolated in fall or winter 
(Figure 2).
CrP levels and etiology of exacerbations
Median CRP levels from the 265 episodes with full microbio-
logical analyses were higher in cases with positive cultures 
for bacteria (58.3 mg/L, IQR 21.0–128.2) than in episodes 
only positive for viruses (37.3 mg/L, IQR 18.6–79.1) 
and cases negative for any microorganism (36.4 mg/L, 
IQR 10.8–93.7) (P,0.014). In bacterial infections, 
CRP reached the highest levels in exacerbations due to 
S. pneumoniae (74.1, IQR 42.0–220.7) and H. influenzae 
(74.5, IQR 23.9–167.9) in comparison with episodes related 
1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1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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Figure 1 Flowchart for sputum samples included in the study.
Abbreviation: rT-PCr, retrotranscriptase-nested polymerase chain reaction.
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to P. aeruginosa (45.2, IQR 11.1–70.1) or infections due 
exclusively to viruses (37.3, IQR 18.6–79.1) (Table 2). CRP 
was not related with bacterial load except for S. pneumoniae, 
in which a significant correlation was observed (Figure 3). 
Episodes due to S. pneumoniae also reported fever (15, 
56%) and required hospital admission (17, 60.7%) more 
frequently than other microorganisms (P=0.061 and 0.002, 
respectively). Self-reported upper airway symptoms were 
similar across the groups (Table 2).
CrP and exacerbation severity
In the 380 exacerbations studied, significant differences in 
CRP levels were found between community-attended epi-
sodes (37.3 mg/L, IQR 12.8–82.7) and hospitalized episodes 
(67.4 mg/L, IQR 27.0–189.0).
Other markers of exacerbation severity such as RR, 
SaO
2
, PaO
2
, and PaCO
2
 were also associated with the need 
for hospital admission (Table 3). The increase in CRP was 
significantly associated with increases in RR and leukocytes, 
and a fall in SaO
2
 (rho =0.143; P=0.012, rho =0.270; P,0.01 
and rho =-0.185; P,0.01, respectively). In the GEE model 
for assessing the influence of inflammatory response on 
exacerbation severity, CRP emerged as predictive, along 
with long-term oxygen therapy and baseline hypercapnia. 
When adjusted for clinical variables and comorbidities, both 
basal hypercapnia and CRP remained in the model, with 
a fourfold risk of hospital admission when the CRP level 
was .100 mg/L (Table 4).
Discussion
In a well-characterized cohort of severe COPD patients with 
Anthonisen type I–II exacerbations, systemic inflamma-
tion, as measured by CRP, was associated with a bacterial 
etiology (mainly S. pneumoniae or H. influenzae), and with 
bacterial load when S. pneumoniae was the causative agent. 
CRP, additionally, was a good predictor of the severity of 
the exacerbations; patients with CRP levels .100 mg/L 
presented a fourfold increase in hospitalization. Basal hyper-
capnia emerged as an additional predictor of admission in the 
cohort. Thus, CRP emerges as a good biological marker for 
the identification of severe exacerbations in COPD patients 
with advanced disease, mainly related to bacterial infections 
due to S. pneumoniae and H. influenzae.
The prevalence of infection in severe COPD outpatients in 
our study was 80%, with figures .60% for bacteria and ~40% 
for viruses, one-half of them as coinfections with pathogenic 
bacteria. These data are similar to those obtained in other 
studies that have focused on patients requiring hospitaliza-
tion due to the severity of the episode,26,27 suggesting that this 
etiologic pattern characterizes severe COPD exacerbations. 
H. influenzae was the most frequently recovered bacteria in 
the present study and was the cause of one-quarter of the 
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Figure 2 seasonal pattern of virus detection in episodes of acute exacerbation (ae) 
of COPD (265 episodes analyzed).
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 2 Clinical characteristics and inflammatory biomarkers by microorganism (N=265)*
HI, n=66 SP, n=28 MC, n=28 PS, n=28 Other, n=17 Negative, 
n=53
Only virus, 
n=45
P-value$
Fever (%)+ 40 56 36 11.5 33.3 41.7 34.9 0.061
Uas (%)# 26.2 17.9 28.6 5.6 6.0 18.4 25.6 0.315
WBC count,  
median (IQr)
10,480  
(8,560–12,970)
11,500  
(9,670–14,740)
9,420  
(7,862–9,420)
8,985  
(7,927–10,365)
9,250  
(6,740–13,250)
10,435  
(8,487–11,427)
9,585  
(7,230–11,355)
0.039
CrP (mg/l),  
median (IQr)
74.50  
(23.90–167.90)
74.10 
(42.0–220.7)
38.10  
(20.60–95.40)
45.20  
(11.10–70.10)
51.90  
(23.60–166.0)
36.40  
(10.80–93.70)
37.30  
(18.60–79.10)
0.026
hospital admission (%) 47 60.7 21.4 57 41.1 22.6 37.8 0.002
Notes: *Primary pathogen included; when more than two bacteria were isolated, the higher bacterial load was analyzed. +Missing values: 1 in hI group, 1 in sP, 3 in MC, 
2 in Ps, 2 in Other, 5 in negative, and 2 in Only virus. #Missing values: 1 in hI, 4 in negative, and 2 in Only virus. $Chi-squared across all groups (median test in case of 
continuous variables).
Abbreviations: CrP, C-reactive protein; hI, Haemophilus influenzae; IQr, interquartile range; MC, Moraxella catarrhalis; Ps, Pseudomonas aeruginosa; sP, Streptococcus 
pneumoniae; Uas, upper airway symptoms; WBC, white blood cell.
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exacerbations, followed by S. pneumoniae, M. catarrhalis, 
and P. aeruginosa. Consistent with other reports, RVs were 
the most frequently detected virus in our study, in 30% of the 
cases as a coinfection with pathogenic bacteria.27,6
CRP levels in peripheral blood were clearly related to 
the etiology of the exacerbation in the study population, 
with the highest figures for S. pneumoniae and H. influenzae 
and a statistically significant relationship between bacte-
rial load and blood levels of this inflammatory marker for 
S. pneumoniae. The systemic impact of this PPM has been 
assessed in patients with pneumonia; it is related to sever-
ity and prognosis9,28 and is determined by a host–pathogen 
interaction favored by the C-polysaccharide of the pneumo-
coccal cell wall.29 The inflammatory power of H. influenzae 
in the bronchial tree is well known and has been related to 
microbial load,10 but the systemic effect of this PPM has 
been studied only marginally. The present results confirm 
that bronchial infections due to H. influenzae have a clear 
systemic effect in severe COPD patients, as measured by 
CRP levels in peripheral blood, equivalent to the effect 
found in S. pneumoniae-related exacerbations. This finding 
is clinically significant, because H. influenzae is the most 
prevalent cause of exacerbation in these patients; infections 
by H. influenzae and S. pneumoniae were the cause of nearly 
one-half of the episodes. In contrast, virus detection was 
associated with lower CRP levels and severity. Our results 
are at odds with those of previous studies that have reported 
higher levels of serum CRP in patients with virus-induced 
exacerbations.6,11 The differences are probably due to the 
characteristics of the episodes reported here, consisting of 
exacerbations that appear in the follow-up of a cohort of 
severe COPD outpatients. Previous studies have focused 
on severe exacerbations requiring hospitalization and have 
thus missed milder episodes that may be partially related to 
viruses and probably evolve with lower CRP levels.
Unfortunately, as previously reported,7 CRP levels were 
unable to predict etiology due to the overlapping of levels 
between the different microorganisms.
In our study, CRP levels were clearly related to the need 
for hospitalization; with CRP .100 mg/L, the probability of 
admission rose more than fourfold. These high CRP figures 
were mainly related to bacterial infections by S. pneumoniae 
and H. influenzae. This relationship did not depend on the 
covariates assessed and supports a role for this inflamma-
tory marker in the management of exacerbations appearing 
in severe COPD outpatients; however, in previous studies, 
it did not prove valuable in predicting outcome.12,30 Our 
study suggests similarities with pneumonia in relation to 
the significance of CRP for the management of these enti-
ties. In fact, a cutoff .100 mg/L has been associated with 
adverse outcomes28 and demonstrated a predictive ability 
for selecting patients requiring intensive care unit (ICU) 
admission.31 Similar values of CRP have been reported in 
COPD exacerbations for selecting patients requiring ICU 
admission, although the number of patients included (n=64) 
was too small to draw conclusions.32
Our study also underlined the importance of baseline 
hypercapnia as a marker of severity in acute episodes, in 
Figure 3 relationship between bacterial load and CrP (spearman’s correlation 
coefficient rho =0.92; P=0.006 in exacerbations due to S. pneumoniae).
Abbreviations: cfu, colony forming units; CrP, C-reactive protein; H. influenzae, 
Haemophilus influenzae; M. catarrhalis, Moraxella catarrhalis; P. aeruginosa, Pseudomonas 
aeruginosa; S. pneumoniae, Streptococcus pneumoniae.
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Table 3 Markers of exacerbation severity (n=380)
Reference values Community-managed, n=227 Hospital admitted, n=153 P-value*
CrP ,5 mg/l 37.3 (12.8–82.7) 67.4 (27.0–189.0) ,0.0001
WBC count 4,000–11,000 9,900 (7,860–11,460) 10,030 (8,500–14,002) 0.001
rr 12–16 breath/min 24 (20–28) 26 (24–30) 0.002
saO2 96%–100% 94 (92–95) 89 (85–92) ,0.0001
PaO2
+ 10.6–13.3 KPa 7.9 (7.3–8.6) 7.0 (6.2–7.6) 0.002
PaCO2
+ 4.6–5.9 KPa 5.7 (5.2–6.6) 6.2 (5.4–7.5) 0.001
ph+ 7.35–7.45 7.42 (7.40–7.44) 7.41 (7.39–7.44) 0.443
Notes: *Univariate generalized estimating equation. +Only obtained in 197 episodes. Data presented as median (interquartile range).
Abbreviations: CrP, C-reactive protein; IQr, interquartile range; min, minutes; rr, respiratory rate; WBC, white blood cell.
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Table 4 analysis of factors associated with hospital admission. results of univariate and multivariate gee
OR (95% CI) P-value OR (95% CI) P-value
gOlD stage IV 1.28 (0.75–2.18) 0.36 – –
Charlson Comorbidity Index 1.15 (0.95–1.40) 0.14 1.12 (0.95–1.32) 0.15
Bronchiectasis 1.39 (0.78–2.47) 0.26 – –
BODe 1.13 (0.93–1.37) 0.21 – –
lTOT 1.89 (1.08–3.32) 0.02 1.14 (0.61–2.13) 0.67
Baseline hypercapnia 2.69 (1.56–4.64) ,0.0001 2.70 (1.46–4.9) 0.01
CrP (mg/l)
,18.6 1 1
18.7–47.7 1.74 (0.91–3.33) 0.09 1.64 (0.85–3.15) 0.13
47.8–100 2.56 (1.25–5.24) 0.01 2.21 (1.05–4.68) 0.03
.100 4.44 (2.25–8.78) ,0.0001 4.23 (2.12–8.44) ,0.0001
Note: CrP data is presented as quartiles.
Abbreviations: BODE, Body-mass index, airflow Obstruction, Dyspnea, and Exercise index; CI, confidence interval; CRP, C-reactive protein; GEE, generalized estimating 
equation; gOlD, global Initiative for Chronic Obstructive lung Disease; lTOT, long-term oxygen therapy; Or, odds ratio.
agreement with previous studies that have associated this 
abnormality with survival.33 Baseline hypercapnia doubled 
the risk of hospital admission and it seems reasonable to 
think that it identified a subgroup of more frail patients, at 
least in our cohort.
In two studies with exacerbated COPD patients,34,35 the 
addition of arterial blood gas parameters (oxygen and carbon 
dioxide partial pressures and pH) did not improve the pre-
diction of mortality during hospitalization, but was closely 
related with need for admission. However, no baseline data 
were recorded in these studies.
Limitations
The present study has some limitations related to patient 
selection. Participants were from a severe COPD population 
regularly attending a respiratory daycare unit, and our results 
cannot be extrapolated to the COPD population as a whole. 
The number of episodes recorded in the different patients 
also varied widely. Even though we used a GEE approach to 
overcome this problem, we cannot rule out a possible over-
representation of a particular subset of patients who may be 
more susceptible to specific microorganisms.
Finally, infections with uncommon respiratory viruses 
such as metapneumovirus and bocavirus were not evaluated 
in our study, and the true prevalence of virus infection may 
therefore be slightly underestimated.
Conclusion
In conclusion, this study demonstrated a high prevalence of 
bacterial infection, mainly due to H. influenzae, S. pneumoniae, 
M. catarrhalis, and P. aeruginosa in exacerbations appearing 
in severe COPD outpatients. The prevalence of viral infec-
tions was significantly lower. Systemic inflammation 
identified through CRP blood levels was higher in bacterial 
infections, mainly when H. influenzae and S. pneumoniae 
were the cause, and high figures for this inflammatory 
biomarker were related to the severity of the episode. The 
findings suggest that CRP blood levels may be a useful 
biomarker in the management of exacerbations appearing 
in these severe patients.
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